대한종양외과학회지 (Korean Journal of Clinical Oncology)

  • 제14권2호
  • /
  • Pages.116-119
  • /
  • 2018
  • /
  • 1738-8082(pISSN)
  • /
  • 2288-4084(eISSN)
대한종양외과학회 (Korean Society of Surgical Oncology)
권호 표지
DOI QR코드

DOI QR Code

The efficacy of chemotherapy in the patients with stage II colon cancer associated with number of high-risk factors

  • Kim, Min Joo (Department of Surgery, Biomedical Research Institute, Pusan National University Hospital) ;
  • Baek, Seung-hyun (Department of Surgery, Biomedical Research Institute, Pusan National University Hospital) ;
  • Ko, Sanghwa (Department of Surgery, Busan Medical Center)
  • 투고 : 2017.10.25
  • 심사 : 2018.12.18
  • 발행 : 2018.12.31
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: This study assessed the effect of chemotherapy over stage II colon cancer in terms of presence of high-risk factors. Methods: Data were retrospectively reviewed for 364 patients with stage II colon cancer who underwent curative surgery between January 2007 and December 2012. High-risk factors of stage II colon cancer were examined, and the overall survival (OS) rates were analyzed. Survival benefit of adjuvant chemotherapy was also analyzed. Results: One hundred and fifteen cases had exclusively single high-risk factor and 194 cases were negative for high-risk factors. Postoperative chemotherapy was performed in 262 of 364 patients (72.0%). The 5-year OS was 79.4% and 86.6% for patients without adjuvant chemotherapy and those with chemotherapy, respectively. The 5-year OS was 88.2% and 83.3% for patients having exclusively single high-risk factor with adjuvant chemotherapy and those without chemotherapy, respectively. Conclusion: Adjuvant chemotherapy for patients with stage II colon cancer having exclusively single high-risk factor could be omitted, weighing up the survival benefit and side effect of chemotherapy.

키워드

참고문헌

  1. Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, et al. Localized colon cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2013;11:519-28. https://doi.org/10.6004/jnccn.2013.0069
  2. Marshall JL, Haller DG, de Gramont A, Hochster HS, Lenz HJ, Ajani JA, et al. Adjuvant therapy for stage II and III colon cancer: consensus report of the International Society of Gastrointestinal Oncology. Gastrointest Cancer Res 2007;1:146-54.
  3. Burdy G, Panis Y, Alves A, Nemeth J, Lavergne-Slove A, Valleur P. Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum 2001;44:1682-8. https://doi.org/10.1007/BF02234390
  4. Fujita S, Nakanisi Y, Taniguchi H, Yamamoto S, Akasu T, Moriya Y, et al. Cancer invasion to Auerbach's plexus is an important prognostic factor in patients with pT3-pT4 colorectal cancer. Dis Colon Rectum 2007;50:1860-6. https://doi.org/10.1007/s10350-007-9072-8
  5. Suzuki T, Suwa K, Ogawa M, Eto K, Kawahara H, Fujita T, et al. Adjuvant chemotherapy for the perineural invasion of colorectal cancer. J Surg Res 2015;199:84-9. https://doi.org/10.1016/j.jss.2015.03.101
  6. Knijn N, Mogk SC, Teerenstra S, Simmer F, Nagtegaal ID. Perineural invasion is a strong prognostic factor in colorectal cancer: a systematic review. Am J Surg Pathol 2016;40:103-12. https://doi.org/10.1097/PAS.0000000000000518
  7. Huh JW, Lee JH, Kim HR, Kim YJ. Prognostic significance of lymphovascular or perineural invasion in patients with locally advanced colorectal cancer. Am J Surg 2013;206:758-63. https://doi.org/10.1016/j.amjsurg.2013.02.010
  8. O'Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011;29:3381-8. https://doi.org/10.1200/JCO.2010.34.3426
  9. Casadaban L, Rauscher G, Aklilu M, Villenes D, Freels S, Maker AV. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer. Cancer 2016;122:3277-87. https://doi.org/10.1002/cncr.30181
  10. Verhoeff SR, van Erning FN, Lemmens VE, de Wilt JH, Pruijt JF. Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer. Int J Cancer 2016;139:187-93. https://doi.org/10.1002/ijc.30053
  11. Babcock BD, Aljehani MA, Jabo B, Choi AH, Morgan JW, Selleck MJ, et al. High-risk stage II colon cancer: not all risks are created equal. Ann Surg Oncol 2018;25:1980-5. https://doi.org/10.1245/s10434-018-6484-8
  12. Brearley SG, Craven O, Saunders M, Swindell R, Molassiotis A. Clinical features of oral chemotherapy: results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK. Eur J Cancer Care (Engl) 2010;19:425-33.
  13. Kopec JA, Yothers G, Ganz PA, Land SR, Cecchini RS, Wieand HS, et al. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 2007;25:424-30. https://doi.org/10.1200/JCO.2005.05.2597
  14. Law CC, Fu YT, Chau KK, Choy TS, So PF, Wong KH. Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with stage III colon cancer. Dis Colon Rectum 2007;50:2180-7. https://doi.org/10.1007/s10350-007-9045-y
  15. Pfeiffer P, Mortensen JP, Bjerregaard B, Eckhoff L, Schonnemann K, Sandberg E, et al. Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. Eur J Cancer 2006;42:2738-43. https://doi.org/10.1016/j.ejca.2006.06.027

피인용 문헌

  1. Adjuvant chemotherapy in patients with stage II colon cancer vol.14, pp.2, 2018, https://doi.org/10.14216/kjco.18012